<div id="readability-page-1"><p><span>InflaRx (NASDAQ:IFRX - Get Free Report)</span>'s stock had its &#34;buy&#34; rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright's price target would indicate a potential upside of 482.52% from the stock's previous close.</p><p>A number of other equities analysts have also commented on the company. Leerink Partnrs lowered InflaRx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, December 3rd. Raymond James Financial  reaffirmed an &#34;outperform&#34; rating on shares of InflaRx in a report on Tuesday, November 11th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of InflaRx in a report on Monday, December 22nd. Leerink Partners  reaffirmed a &#34;market perform&#34; rating and set a $2.00 price target (down previously from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Finally, Guggenheim increased their price objective on shares of InflaRx from $10.00 to $22.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, November 10th. Five analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $7.50.</p><p><b>Get Our Latest Report on InflaRx</b></p><h2>InflaRx Stock Up 1.0%</h2><p>IFRX traded up $0.01 during midday trading on Tuesday, reaching $1.03. The company had a trading volume of 1,108,669 shares, compared to its average volume of 1,081,028. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.77. The company has a market cap of $69.14 million, a P/E ratio of -1.52 and a beta of 1.46. The business has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.12. </p><p>InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million.  On average, equities research analysts predict that  InflaRx will post -1.04 EPS for the current year. </p><h2>Hedge Funds Weigh In On InflaRx</h2><p>Several hedge funds have recently bought and sold shares of IFRX. Cubist Systematic Strategies LLC lifted its stake in  InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after acquiring an additional 7,616 shares during the period.  683 Capital Management LLC increased its position in  InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock valued at $2,678,000 after purchasing an additional 555,000 shares during the period.  Woodline Partners LP bought a new stake in shares of  InflaRx in the 1st quarter valued at about $766,000.  Concurrent Investment Advisors LLC purchased a new stake in shares of  InflaRx in the 2nd quarter worth approximately $65,000.  Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of  InflaRx by 158.3% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock valued at $118,000 after purchasing an additional 91,927 shares in the last quarter. Institutional investors own  42.39% of the company's stock. </p><h2>InflaRx Company Profile</h2> (Get Free Report)<p>InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.  </p><p>Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than InflaRx</li><li>Americans can target 100%+ wins during “Operation Motherlode”</li><li>Trump’s new AI budget just passed — one stock could soar</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>Chilling warning from legendary investor</li><li>Buy this $2 Gold Stock Before January 1, 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in InflaRx Right Now?</h2><p>Before you consider InflaRx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p><p>While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IFRX

<p>HC Wainwright has restated a "buy" rating for InflaRx (NASDAQ:IFRX) with a price target of $6.00, indicating a potential upside of 482.52% from its previous close. Other analysts have varied opinions, with some lowering ratings and price targets. Currently, five analysts rate the stock as a buy, two as hold, and one as sell, leading to an average rating of "Moderate Buy" with a consensus target price of $7.50. InflaRx's stock is currently trading at $1.03, with a market cap of $69.14 million and a P/E ratio of -1.52.</p>

InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright